1h Free Analyst Time
The Chronic Refractory Cough Market grew from USD 5.57 billion in 2023 to USD 5.88 billion in 2024. It is expected to continue growing at a CAGR of 5.88%, reaching USD 8.32 billion by 2030. Speak directly to the analyst to clarify any post sales queries you may have.
Rising incidences of chronic respiratory conditions such as asthma, COPD, and bronchitis naturally lead to an increase in cases of chronic refractory coughs. Improved healthcare infrastructure and heightened awareness about CRC have led more individuals to seek treatment for chronic coughs, thus expanding the market. Innovative therapeutic approaches and advancements in medical technologies that offer higher efficacy in treating or managing CRC are also critical growth drivers in the market. However, CRC can often be misdiagnosed or overlooked as its symptoms may resemble those of other less severe illnesses, which can impede effective treatment. Some current treatments available have significant side effects, which might deter patients, creating challenges for continuing with their prescribed therapies. Moreover, there is a substantial opportunity for growth through the development of new pharmaceutical formulations and advanced therapeutic devices designed specifically for CRC management. Integrating CRC management with telehealth platforms can enhance accessibility for patients struggling with this condition, facilitating continuous management without frequent hospital visits.
Regional Insights
In the Americas region, the U.S. and Canada represent a substantial market for the management of chronic refractory cough due to its advanced healthcare infrastructure and high awareness levels regarding respiratory conditions. Recent patents in the U.S. have focused on novel cough suppressant therapies and cough management devices, highlighting a trend toward technological integration in treatment. The EU market is guided by stringent regulations that drive the demand for highly effective and safe treatments. Consumer behavior in the EU is characterized by a preference for evidence-based therapies. In the Middle East, there is increasing awareness and healthcare expenditure concerning chronic diseases, including CRC. The Middle East region shows growing interest in specialized healthcare services and international collaborations for advanced treatment methods. Recent initiatives in the African region aim to improve healthcare infrastructure and accessibility, which may increase the demand for CRC management solutions in the long term. In the APAC region, China has seen rapid health infrastructure improvements, which extend to the management of chronic coughs. CRC treatment in Japan often involves cutting-edge technology and pharmaceuticals supported by government-backed healthcare policies. Japan’s aging population also makes it a critical market for CRC management solutions. In India, the rising middle class and improvements in healthcare facilities are creating significant opportunities for CRC management.Market Insights
Market Dynamics
- The market dynamics represent an ever-changing landscape of the Chronic Refractory Cough Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
Market Drivers
- Rising prevalence of chronic refractory cough
- Government support for awareness and early diagnosis
Market Restraints
- Potential risk of drug recall
Market Opportunities
- Increasing R&D initiatives toward effective drug development
- Collaborative drug development and improving healthcare expenditure
Market Challenges
- Side effects associated CRC treatment
Market Segmentation Analysis
- Drug Type: Exploring gabapentin for innovative treatments for chronic refractory cough with neuropathic links
- Distribution Channel: Increasing preference to online pharmacies for chronic refractory cough treatment
Industry Insights
- Market Disruption Analysis
- Porter’s Five Forces Analysis
- Value Chain & Critical Path Analysis
- Pricing Analysis
- Technology Analysis
- Patent Analysis
- Trade Analysis
- Regulatory Framework Analysis
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Chronic Refractory Cough Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Chronic Refractory Cough Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.Recent Developments
Investment Surge in Novel Respiratory Therapeutics: Focus on Nocion Therapeutics' Development of Taplucanium for Chronic Refractory Cough
Nocion Therapeutics, based in Watertown, Massachusetts, has completed a USD 62 million Series B funding round to advance the development of their innovative drug, taplucanium. Nocion is pioneering a novel approach by targeting the nociceptors - sensory neurons that trigger pain, itching, or coughs - which are implicated in various conditions including chronic refractory cough, a difficult-to-treat condition characterized by a persistent cough without a clear underlying causeTrevi Therapeutics Launches Phase 2a RIVER Trial for Haduvio, Advancement in Refractory Chronic Cough Treatment
Trevi Therapeutics, Inc., a pioneering company in clinical-stage biopharmaceuticals, recently initiated the Phase 2a RIVER clinical trial to assess the efficacy of Haduvio (oral nalbuphine ER) in treating patients with refractory chronic cough (RCC). The RIVER trial, a rigorous double-blind, placebo-controlled study with a 2-period crossover design, aims to enroll approximately 60 participants who suffer from moderate to severe cough frequenciesGSK PLC Finalizes Acquisition of BELLUS Health Inc. Health to Enhance Chronic Refractory Cough Treatment Portfolio
GSK PLC has acquired BELLUS Health Inc., integrating BELLUS Health Inc.'s promising drug candidate, camlipixant, a highly selective P2X3 antagonist into its respiratory therapy lineup. Camlipixant, now in phase III trials, targets the first line treatment of adult patients with refractory chronic cough. The transaction, endorsed by BELLUS Health Inc. shareholders to leverage GSK PLC's robust R&D, manufacturing, and commercialization capabilities to expedite the drug's market launch.Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Chronic Refractory Cough Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.Key Company Profiles
The report delves into recent significant developments in the Chronic Refractory Cough Market, highlighting leading vendors and their innovative profiles. These include Accord Healthcare Inc., Alitair Pharmaceuticals, Amneal Pharmaceuticals Inc., Apotex Inc., AstraZeneca PLC, Aurobindo Pharma Ltd, Bausch Health, Bayer AG, Cipla Inc., Dr Reddy's Laboratories Ltd., Glenmark Pharmaceuticals Ltd., GSK PLC, Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Mylan N.V. by Viatris Inc., NeRRe Therapeutics, Novartis AG, Pfizer Inc., Sienna Biotec, Strides Pharma, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Unichem Laboratories Ltd. by Ipca Labs, and Zydus Pharmaceuticals USA Inc..Market Segmentation & Coverage
This research report categorizes the Chronic Refractory Cough Market to forecast the revenues and analyze trends in each of the following sub-markets:Drug Type
- Amitriptyline
- Gabapentin
- Pregabalin
Distribution Channel
- Drug Store
- Hospital Pharmacies
- Online Pharmacies
Region
Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
Additional Product Information:
- Purchase of this report includes 1 year online access with quarterly updates
- This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website
Table of Contents
1. Preface
2. Research Methodology
5. Market Insights
6. Chronic Refractory Cough Market, by Drug Type
7. Chronic Refractory Cough Market, by Distribution Channel
8. Americas Chronic Refractory Cough Market
9. Asia-Pacific Chronic Refractory Cough Market
10. Europe, Middle East & Africa Chronic Refractory Cough Market
11. Competitive Landscape
12. Competitive Portfolio
List of Figures
List of Tables
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Accord Healthcare Inc.
- Alitair Pharmaceuticals
- Amneal Pharmaceuticals Inc.
- Apotex Inc.
- AstraZeneca PLC
- Aurobindo Pharma Ltd
- Bausch Health
- Bayer AG
- Cipla Inc.
- Dr Reddy's Laboratories Ltd.
- Glenmark Pharmaceuticals Ltd.
- GSK PLC
- Hikma Pharmaceuticals PLC
- Intas Pharmaceuticals Ltd.
- Mylan N.V. by Viatris Inc.
- NeRRe Therapeutics
- Novartis AG
- Pfizer Inc.
- Sienna Biotec
- Strides Pharma
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceutical Industries Ltd.
- Torrent Pharmaceuticals Ltd.
- Unichem Laboratories Ltd. by Ipca Labs
- Zydus Pharmaceuticals USA Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 182 |
| Published | June 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 5.88 Billion |
| Forecasted Market Value ( USD | $ 8.32 Billion |
| Compound Annual Growth Rate | 5.8% |
| Regions Covered | Global |
